Boston Scien Cp Stock Price, News & Analysis

Boston Scientific Corporation (NYSE: BSX) will present at the 2020 Evercore ISI HealthCONx Conference on December 1. The session will feature CEO Mike Mahoney and VP of Investor Relations Susie Lisa, starting at approximately 8:00 a.m. EST. A live webcast and replay of the event will be available at investors.bostonscientific.com, accessible one hour after the session concludes. Boston Scientific is a leader in medical technology, providing innovative solutions that enhance patient care globally.

Boston Scientific (BSX) has announced a global voluntary recall of all unused LOTUS Edge Aortic Valve System inventory due to complexities with its delivery system. This recall will not affect patients who already have the valve implanted. The company will retire the entire LOTUS product platform, ceasing all related activities. This decision is estimated to incur pre-tax GAAP charges of $225 million to $300 million, with a significant portion impacting adjusted results. The expected effect on earnings per share for 2021 is a slight increase of 1 to 2 cents.

Boston Scientific Corporation (NYSE: BSX) will participate in two virtual investor conferences in November 2020. On November 12, Meghan Scanlon and Susie Lisa will engage in a Q&A session at the Credit Suisse Virtual Healthcare Conference at 8:00 a.m. EST. On November 18, Dan Brennan and Susie Lisa will take part in a Q&A at the Stifel 2020 Virtual Healthcare Conference starting at 8:40 a.m. EST. Live webcasts will be available at investors.bostonscientific.com, with replays accessible an hour after each event.

Boston Scientific (BSX) has received FDA approval for the Ranger™ Drug-Coated Balloon, aimed at treating peripheral artery disease (PAD) in the superficial femoral and proximal popliteal arteries. With around 200 million affected globally, the Ranger DCB features a low therapeutic drug dose, resulting in high primary patency rates and reduced systemic drug exposure. In pivotal trials, it achieved 94.1% major adverse event freedom and an 82.9% primary patency rate at 12 months, outperforming standard treatments. The device is set to launch in the US following its CE mark in 2014.

Boston Scientific (NYSE: BSX) has launched the CHAMPION-AF clinical trial to assess the safety and effectiveness of the WATCHMAN FLX™ device for patients with non-valvular atrial fibrillation (NVAF). This study will involve 3,000 patients at about 150 sites globally, comparing the device against non-vitamin K antagonist oral anticoagulants (NOACs). The trial aims to provide evidence for making the WATCHMAN FLX a potential first-line therapy for stroke prevention. The device offers a one-time solution, crucial for patients who cannot tolerate long-term anticoagulation.

Boston Scientific Corporation (BSX) reported third-quarter 2020 sales of $2.659 billion, a decline of (1.8)% year-over-year. The company faced a GAAP net loss of $(169) million or $(0.12) per share, compared to a profit of $126 million or $0.09 per share last year. Adjusted EPS was $0.37, down from $0.39. Sales decreased across all segments, notably a (16.3)% drop in Interventional Cardiology. New product launches include FDA-approved devices such as the AVVIGO Guidance System and SYNERGY Stent Systems. The company refrained from issuing guidance due to COVID-19 uncertainty.

Boston Scientific (NYSE: BSX) will host a virtual investor update at the 2020 Transcatheter Cardiovascular Therapeutics on October 15, from 1:00 to 2:00 p.m. EDT. Key executives will discuss the cardiovascular portfolio and address investor questions. Additionally, on October 28, the company will conduct a conference call at 8:00 a.m. EDT to review third-quarter financial results for the period ending September 30, with a news release preceding it. Both events will be accessible via the company's investor relations webpage.

Boston Scientific has launched the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) Systems in Europe, designed to provide personalized pain relief for chronic pain sufferers. This new portfolio includes four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs). The WaveWriter Alpha systems support combination therapy, allowing for simultaneous use of different stimulation modalities. With 88% of patients reporting significant pain relief, this launch aims to enhance quality of life for the approximately 100 million people in Europe affected by chronic pain.

Boston Scientific (NYSE: BSX) has launched the ACURATE neo2™ Aortic Valve System in Europe, enhancing transcatheter aortic valve implantation (TAVI) technology. This system offers expanded indications for patients with aortic stenosis, includes new annular sealing technology to minimize paravalvular regurgitation, and simplifies access to complex vessels. Clinical data suggests improved outcomes, with 97.5% of patients experiencing mild or no paravalvular leakage at one year. The system is investigational in the U.S., assessed in the ACURATE IDE trial.